AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02336282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain Games Stimulation
Description: Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
Study NCT01574586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bifurcation stenting
Description: Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
Study NCT02728180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
Study NCT02728180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.
Study NCT02728180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.
Study NCT03755921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bried and intensive therapy
Description: Speech Therapy Exercises
Study NCT03755921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bried and intensive therapy
Description: Speech Therapy Exercises
Study NCT04546035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radial Extracorporeal Shockwave Therapy
Description: rESWT was given on hamstring muscles, with the subject lying on prone position. No anesthesia was required.
Study NCT00657540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analatro
Description: 30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
Study NCT00657540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 50 mL of saline infused over 10 minutes
Study NCT03552666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Study NCT03552666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Study NCT06125366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1747846
Description: Single dose; IV injection.
Study NCT06125366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Single dose; IV injection.
Study NCT01848665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Study NCT01848665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01796925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aura6000 THN System
Description: The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
Study NCT00602212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation with virtual reality (VR)
Description: VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
Study NCT00602212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation with virtual reality (VR)
Description: VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
Study NCT00602212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation and biofeedback virtual reality
Description: The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
Study NCT00602212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation and biofeedback virtual reality
Description: The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
Study NCT04393675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LT5001
Description: Administered twice daily
Study NCT04393675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice daily
Study NCT02836912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
Study NCT02828371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stepping verticalization
Description: After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
Study NCT02828371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional mobilization
Description: in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
Study NCT03128515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
Study NCT03128515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
Study NCT01316016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rose hip
Description: 40 g of rose hip powder daily for 6 weeks.
Study NCT03880539 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bezlotoxumab
Description: Adding BEZLO to SOC oral VAN pulse/taper
Study NCT03880539 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin Oral
Description: SOC vancomycin pulse/taper
Study NCT01439789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhNRG-1
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study NCT02842827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: oral administration
Study NCT01439789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study NCT03741153 — intervention group
Intervention type: DEVICE
Intervention: slit lamp
Description: 1. Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~2. Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~3. The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~4. presence of PXF material scattered on corneal endothelium.~5. Flecks of the exfoliative material on the anterior chamber which leads to glaucoma.
Study NCT05051748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching
Study NCT05051748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste
Study NCT05051748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
Study NCT04537975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C2Rx
Description: Hemofiltration
Study NCT04537975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care that excludes any protocol restrictions.
Study NCT03372785 — intervention group
Intervention type: DRUG
Intervention: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Study NCT03372785 — intervention group
Intervention type: DEVICE
Intervention: coronary wires. stents or coronary balloons
Description: all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
Study NCT04541407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide plus Osimertinib
Description: Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide.
Study NCT03915704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocker
Description: Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
Study NCT04541407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide plus Lorlatinib
Description: Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide
Study NCT03684863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: observation
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control toothpaste containing Novamin® technology
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste containing 1500 ppm fluoride as MFP
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP (high concentration)
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP (low concentration)
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste without nano-HAP
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP (medium concentration)
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test cream with nano-HAP (higher concentration)
Study NCT02918617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control cream without nano-HAP
Study NCT03577275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-4016 600mg
Description: Likely maximum therapeutic dose of NST-4016
Study NCT03577275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo for comparison with moxifloxacin and potential NST-4016 effects
Study NCT03577275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Active comparator with known effect on QT interval
Study NCT03577275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-4016 2000mg
Description: Supratherapeutic dose of NST-4016
Study NCT04464863 — intervention group
Intervention type: OTHER
Intervention: Kinematic metrics
Description: kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)
Study NCT04034368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Description: Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
Study NCT02994108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: txt2protect
Description: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
Study NCT02994108 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual Health Control
Description: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
Study NCT02219464 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngeal catheter
Study NCT02219464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Cannula
Study NCT02219464 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oxygen Supplementation
Description: Initially set at 3 liters/minute
Study NCT02219464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Supplementation
Description: Initially set at 3 liters/minute
Study NCT02219464 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sedation
Description: Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
Study NCT02219464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation
Description: Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
Study NCT04834180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet plan
Description: The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.
Study NCT04834180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Hypocaloric diet plan
Description: The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.
Study NCT04834180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular Acupuncture
Description: Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
Study NCT04834180 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupressure
Description: Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
Study NCT04936906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra Care (EC) Intervention
Description: The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.
Study NCT04936906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
Study NCT01102335 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Description: The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
Study NCT01102335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Description: The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
Study NCT01102335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: anti-HBV drug
Study NCT03346434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, subcutaneous (SC)
Study NCT03346434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Solution for injection, subcutaneous (SC)
Study NCT04781335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexycu
Description: This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up.
Study NCT04781335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
Description: This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up.
Study NCT02602366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HEC Placebo Gel
Study NCT02602366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Insert
Study NCT02602366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Film
Study NCT02602366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Intravaginal ring (IVR)
Study NCT01447654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 100 mg for 12 months.
Study NCT01447654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg for 12 months.
Study NCT01925885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI Ablation
Description: PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
Study NCT01925885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM Ablation
Description: Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
Study NCT01218334 — intervention group
Intervention type: DEVICE
Intervention: 12 Lead Glove
Description: Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
Study NCT02149914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ryodoraku
Description: Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication